Drug Index

Mecasermin

 
print

Mechanism :

Mecasermin is an insulin-like growth factor (IGF-1) produced using recombinant DNA technology to replace endogenous IGF-1.


Indication :

• Primary insulin-like growth factor-1 deficiency


Contraindications :

Hypersensitivity to mecasermin or any component of the formulation; patients with closed epiphyses; active or suspected neoplasia; intravenous administration.


Dosing :

Subcutaneous: Children ≥2 years and Adolescents: Initial: 0.04-0.08 mg/kg twice daily; if tolerated for 7 days, may increase by 0.04 mg/kg/dose. Maximum dose: 0.12 mg/kg twice daily.


Adverse Effect :

Heart murmur, dizziness, headache, seizure, hypoglycemia, lipohypertrophy (injection site), thymus hypertrophy, vomiting, arthralgia, limb pain, abnormal tympanometry, fluid in ear (middle ear), hyperacusis, otalgia, otitis media, serous otitis media, tonsillar hypertrophy.


Interaction :

Androgens: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Exceptions: Danazol.
Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.


07/14/2019 07:37:25 Mecasermin
ask a doctor
Ask a Doctor
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0